Table 1 Treatment outcome of the PANSS total score based on site-based and site-independent (remote) ratings in trial participants with schizophrenia experiencing an acute exacerbation of psychosis treated with xanomeline/trospium or placebo for five weeksa.

From: Methods to address functional unblinding of raters in CNS trials

 

PANSS total score: LS mean change from baselineb

LS mean difference

F

p

 

X/T (n = 286)

Placebo (n = 289)

   

Site-based score

−17.6 ± 0.90

−8.5 ± 0.91

−9.1 ± 1.23

54.8

<0.0001

Remote score

−15.8 ± 0.90

−9.1 ± 0.91

−6.7 ± 1.23

29.9

<0.0001

  1. ANCOVA analysis of covariance, LS least squares, PANSS positive and negative syndrome scale, X/T xanomeline/trospium.
  2. aIncludes pooled data from three studies (EMERGENT-1, EMERGENT-2, and EMERGENT-3), based upon available paired data at baseline and endpoint (or early termination) (N = 575).
  3. bResults from ANCOVA model adjusting for baseline PANSS total score, age, sex, study, rater, treatment, and rater by treatment interaction.
Back to article page